GT200200138A - Vacunacion en dosis unica con mycoplasma hyopneumoniae - Google Patents

Vacunacion en dosis unica con mycoplasma hyopneumoniae

Info

Publication number
GT200200138A
GT200200138A GT200200138A GT200200138A GT200200138A GT 200200138 A GT200200138 A GT 200200138A GT 200200138 A GT200200138 A GT 200200138A GT 200200138 A GT200200138 A GT 200200138A GT 200200138 A GT200200138 A GT 200200138A
Authority
GT
Guatemala
Prior art keywords
dose
mycoplasma hyopneumoniae
vaccination
hyo
animal
Prior art date
Application number
GT200200138A
Other languages
English (en)
Inventor
Robin Lee Keich
Lisa Grace Sabbadini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200200138(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200200138A publication Critical patent/GT200200138A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0241Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/87Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A PROCEDIMIENTOS PARA EL TRATAMIENTO O PREVENCION DE UNA ENFERMEDAD O TRASTORNO EN UN ANIMAL CAUSADA POR INFECCION POR MYCOPLASMA HYOPNEUMONIAE (M. HYO), MEDIANTE LA ADMINISTRACION A UN ANIMAL, A APROXIMADAMENTE LOS TRES A DIEZ DIAS DE EDAD, DE UNA DOSIS UNICA DE UNA CANTIDAD EFECTIVA DE UNA VACUNA DE M. HYO.
GT200200138A 2001-07-02 2002-07-02 Vacunacion en dosis unica con mycoplasma hyopneumoniae GT200200138A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30263601P 2001-07-02 2001-07-02

Publications (1)

Publication Number Publication Date
GT200200138A true GT200200138A (es) 2003-05-15

Family

ID=23168589

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200138A GT200200138A (es) 2001-07-02 2002-07-02 Vacunacion en dosis unica con mycoplasma hyopneumoniae

Country Status (42)

Country Link
US (3) US6846477B2 (es)
EP (3) EP1474067B2 (es)
JP (1) JP2005515162A (es)
KR (1) KR20040030785A (es)
CN (3) CN101524532B (es)
AP (1) AP2003002937A0 (es)
AR (1) AR034678A1 (es)
AT (1) ATE412426T2 (es)
AU (1) AU2002309109B2 (es)
BG (1) BG66481B1 (es)
BR (1) BR0210804A (es)
CA (1) CA2451626C (es)
CY (1) CY1108749T1 (es)
CZ (1) CZ305781B6 (es)
DE (1) DE60229666D1 (es)
DK (3) DK2842569T3 (es)
DO (1) DOP2002000431A (es)
EA (1) EA009901B1 (es)
ES (3) ES2312580T5 (es)
GT (1) GT200200138A (es)
HK (4) HK1068250A1 (es)
HR (1) HRP20031079A2 (es)
HU (1) HU230246B1 (es)
IL (1) IL159349A0 (es)
IS (1) IS7076A (es)
MA (1) MA27047A1 (es)
MX (1) MXPA03011599A (es)
NO (1) NO342654B1 (es)
NZ (1) NZ530106A (es)
OA (1) OA12638A (es)
PA (1) PA8549701A1 (es)
PE (1) PE20030285A1 (es)
PL (1) PL209773B1 (es)
PT (3) PT1474067E (es)
SK (1) SK288010B6 (es)
TN (1) TNSN03155A1 (es)
TW (1) TWI329514B (es)
UA (1) UA78707C2 (es)
UY (1) UY27366A1 (es)
WO (1) WO2003003941A2 (es)
YU (1) YU102203A (es)
ZA (1) ZA200309698B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2006056841A1 (en) * 2004-11-24 2006-06-01 Pharmacia & Upjohn Company Llc Multiple-strain mycoplasma hyopneumoniae vaccines
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP3868400A1 (en) 2005-12-29 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
PT2371383E (pt) 2005-12-29 2015-11-24 Boehringer Ingelheim Vetmed Utilização de uma composição imunogénica de pcv2 para atenuar os sintomas clínicos em porcos
EP1991262A4 (en) * 2006-03-03 2009-11-04 Merial Ltd MYCOPLASMA HYOPNEUMONIAE VACCINE
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en) * 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed EFFICIENT PROCESS FOR THE TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS
US8865183B2 (en) 2006-12-15 2014-10-21 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigent
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
RU2489164C9 (ru) * 2007-11-06 2014-01-20 ВАЙЕТ ЭлЭлСи АВИРУЛЕНТНАЯ АДЪЮВАНТНАЯ ЖИВАЯ ВАКЦИНА ПРОТИВ Mycoplasma hyopneumoniae
BRPI0821456A2 (pt) * 2007-12-31 2015-06-16 Boehring Ingelheim Vetmedica Inc Partícula similar à pcv2 orf2 com inserção de aminoácido estranho
CN101236206B (zh) * 2008-01-17 2014-10-15 中国兽医药品监察所 一种猪肺炎支原体重组抗原elisa检测试剂盒
EP2242511A4 (en) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
ES2728949T3 (es) * 2008-06-27 2019-10-29 Zoetis Services Llc Composiciones adyuvantes novedosas
TWI583403B (zh) 2009-06-04 2017-05-21 國立感染症研究所 黴漿菌感染症用疫苗
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2569007T3 (en) 2010-05-11 2016-01-25 Intervet Int Bv VACCINE AGAINST Mycoplasma hyopneumoniae SUITABLE FOR ADMINISTRATION IN PRESENCE OF maternally derived antibodies
RU2722357C2 (ru) * 2010-07-26 2020-05-29 Кью Байолоджикс Инк. Иммуногенные противовоспалительные композиции
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
BR112013004594B1 (pt) * 2010-08-27 2020-07-28 Intervet International B. V. método para a determinação de um conteúdo de antígeno
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
UA115053C2 (uk) 2012-03-07 2017-09-11 Сева Санте Анімаль Композиція, що містить антиген і ліпополісахарид у формі масло-в-воді, та спосіб її використання (варіанти)
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
CN104968365B (zh) 2012-12-28 2018-04-03 勃林格殷格翰动物保健有限公司 支原体疫苗的制备方法
KR102355614B1 (ko) 2012-12-28 2022-01-27 베링거잉겔하임베트메디카게엠베하 마이코플라스마 항원을 포함하는 면역원성 조성물
ES2812552T3 (es) * 2013-02-05 2021-03-17 Agricultural Tech Res Inst Vacuna subunitaria contra Mycoplasma spp.
CN104338125A (zh) * 2013-07-29 2015-02-11 普莱柯生物工程股份有限公司 一种猪肺炎支原体抗原在预防和治疗猪呼吸道疾病综合征方面的应用
AU2014321369B2 (en) 2013-09-19 2020-04-16 Zoetis Services Llc Oil-based adjuvants
KR20220083861A (ko) 2013-10-02 2022-06-20 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Pcv2 orf2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자
ES2714000T3 (es) * 2013-11-21 2019-05-24 Agricultural Tech Res Inst Composición para prevenir y curar una infección por micoplasma
CN105012948B (zh) * 2014-04-18 2019-07-30 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
CN104248753B (zh) * 2014-05-15 2017-07-28 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
WO2016115456A1 (en) 2015-01-16 2016-07-21 Zoetis Services Llc Foot-and-mouth disease vaccine
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
US10519199B2 (en) * 2016-08-12 2019-12-31 Innovac Vaccine composition comprising recombinant protein for preventing swine Mycoplasma infection
RU2668799C1 (ru) * 2017-09-08 2018-10-02 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
CN108101969A (zh) * 2017-11-13 2018-06-01 南京大爻网络科技有限公司 一种与猪支原体肺炎相关的抗原及其应用
RU2695679C1 (ru) * 2018-09-11 2019-07-25 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
RU2759427C2 (ru) * 2019-07-08 2021-11-12 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp
CN117305192A (zh) * 2023-12-01 2023-12-29 北京瑞阳瑞泰生物科技有限公司 一种猪肺炎支原体rt02株、疫苗组合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283840A3 (en) * 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
US5252328A (en) 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
DE3881993T2 (de) 1987-09-18 1993-09-30 Akzo Nv Mycoplasma-Impfstoff.
AU7682091A (en) 1990-04-02 1991-10-30 Synergen, Inc. Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
CA2082155C (en) 1990-05-29 2008-04-15 Krishnaswamy I. Dayalu Swine pneumonia vaccine and method of preparation
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0475185A1 (en) 1990-08-27 1992-03-18 Nippon Flour Mills Co., Ltd. DNA's encoding surface antigen of mycoplasma hyopneumoniae, DNA fragments for primer, recombinant antigenic peptides and diagnostic method of mycoplasmal pneumoniae of swine using same
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
DK0839050T3 (da) 1992-09-28 2004-10-25 Wyeth Corp Fremgangsmåde til at forstærke celleformidlede immunreaktioner
US5530874A (en) 1993-02-02 1996-06-25 3Com Corporation Network adapter with an indication signal mask and an interrupt signal mask
WO1995009870A1 (en) 1993-10-07 1995-04-13 Iowa State University Research Foundation, Inc. Characterization of mycoplasma hyopneumoniae adhesins
ZA953703B (en) 1994-05-10 1996-01-10 American Home Prod Modified live BRSV vaccine
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
ES2224273T3 (es) 1996-09-30 2005-03-01 University Of Arkansas Metodo para producir inmunidad activa por medio de un conjugado de vacuna.
EP0846468B1 (en) 1996-12-05 2004-06-09 Akzo Nobel N.V. Non-virulent mycoplasma synoviae and vaccine thereof
BR9815321A (pt) 1997-11-26 2002-01-02 Univ Iowa State Res Found Inc Vacina de mycoplasma hyopneumoniae recombinante
AU6128900A (en) * 1999-09-29 2001-04-05 Pfizer Products Inc. Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs

Also Published As

Publication number Publication date
US20030109473A1 (en) 2003-06-12
CZ20033466A3 (cs) 2005-06-15
HK1180224A1 (zh) 2013-10-18
IL159349A0 (en) 2004-06-01
UA78707C2 (en) 2007-04-25
CN102872456A (zh) 2013-01-16
SK288010B6 (sk) 2012-10-02
TWI329514B (en) 2010-09-01
PT2842569T (pt) 2019-06-17
MXPA03011599A (es) 2005-03-07
ES2312580T3 (es) 2009-03-01
DK2842569T3 (da) 2019-05-20
CN1551781A (zh) 2004-12-01
CN101524532A (zh) 2009-09-09
EP2027873B8 (en) 2015-11-11
EP1474067B2 (en) 2017-08-16
EP2842569B1 (en) 2019-04-10
HRP20031079A2 (en) 2005-10-31
BG66481B1 (bg) 2015-02-27
UY27366A1 (es) 2003-04-30
OA12638A (en) 2006-06-15
EP1474067B1 (en) 2008-10-29
PE20030285A1 (es) 2003-03-27
TNSN03155A1 (fr) 2005-12-23
PT1474067E (pt) 2008-11-14
EP2027873A1 (en) 2009-02-25
MA27047A1 (fr) 2004-12-20
NO342654B1 (no) 2018-06-25
BR0210804A (pt) 2005-05-03
DK1474067T4 (en) 2017-10-16
DE60229666D1 (de) 2008-12-11
WO2003003941A2 (en) 2003-01-16
CY1108749T1 (el) 2014-04-09
CN101524532B (zh) 2014-03-19
CN102872456B (zh) 2016-01-20
ES2729579T3 (es) 2019-11-04
PL373367A1 (en) 2005-08-22
BG108546A (bg) 2005-02-28
EP2027873B1 (en) 2015-09-09
SK15792003A3 (sk) 2005-09-08
CZ305781B6 (cs) 2016-03-16
PA8549701A1 (es) 2003-01-24
ES2312580T5 (es) 2017-12-11
KR20040030785A (ko) 2004-04-09
EA009901B1 (ru) 2008-04-28
US20050013823A1 (en) 2005-01-20
US6846477B2 (en) 2005-01-25
EP1474067A4 (en) 2005-08-10
ES2550458T3 (es) 2015-11-10
DOP2002000431A (es) 2003-01-15
CN1551781B (zh) 2013-01-02
AP2003002937A0 (en) 2003-12-31
CA2451626A1 (en) 2003-01-16
CA2451626C (en) 2011-05-31
IS7076A (is) 2003-12-15
YU102203A (sh) 2006-05-25
EA200301323A1 (ru) 2005-06-30
NO20035762L (no) 2004-02-02
HUP0400434A2 (en) 2007-08-28
DK2027873T3 (en) 2015-11-09
PT2027873E (pt) 2015-11-03
USRE44399E1 (en) 2013-07-30
JP2005515162A (ja) 2005-05-26
ATE412426T2 (de) 2008-11-15
HK1134900A1 (en) 2010-05-20
EP2842569A1 (en) 2015-03-04
DK1474067T3 (da) 2008-12-08
AR034678A1 (es) 2004-03-03
AU2002309109B2 (en) 2007-12-13
HK1068250A1 (en) 2005-04-29
HK1207584A1 (en) 2016-02-05
NZ530106A (en) 2007-06-29
WO2003003941A3 (en) 2004-07-29
ZA200309698B (en) 2014-04-30
PL209773B1 (pl) 2011-10-31
HU230246B1 (hu) 2015-11-30
EP1474067A2 (en) 2004-11-10

Similar Documents

Publication Publication Date Title
GT200200138A (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
AR054844A1 (es) Vacuna contra lawsonia y metodos de uso de la misma
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
CY1108436T1 (el) Χορηγηση καψαϊκινοειδων
CY1112851T1 (el) Μεθοδος προληψης ή θεραπειας μολυνσης μ. τuβεrculosis
UY27186A1 (es) Formulación farmacéutica
CR10726A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
AR054139A1 (es) Formulacion modificada y de liberacion inmediata de esferas de memantina
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
UY28398A1 (es) Método y parche de inmunización por disposición de microproyección
ECSP21051833A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
ECSP21023398A (es) Dosis unitaria de vacuna contra el dengue y administración de esta
PA8549801A1 (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
UY25544A1 (es) Forma de dosificación de nefazodona
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
AR032151A1 (es) Uso de un farmaco anti-angiogenico en conjunto con un agente fotosensible para la preparacion de un medicamento para el tratamiento fotodinamico mejorado de la neovasculatura indeseada
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
GT200300064A (es) Formulacion farmaceutica que comprende melatonina
AR036355A1 (es) Modelo de exposicion a mycoplasma bovis, para evaluar la eficacia de potenciales vacunas
AR048671A1 (es) Procedimiento de vacunacion contra la infeccion testicular por bvdv
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
CL2004000767A1 (es) Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos.
DK2050463T3 (da) Vaccinesammensætning til vaccination af hunde mod hundeinfektiøs respiratorisk sygdom (CIRD)